Measuring albuminuria in patients with hypertension, CKD, or diabetes helps identify those at increased cardiovascular risk who may benefit from cardioprotective treatments.
Does screening for albuminuria help evaluate cardiovascular risk in patients with cardio-kidney-metabolic syndrome?
Patients with arterial hypertension, chronic kidney disease, or diabetes (Cardio-kidney-metabolic syndrome)
Albuminuria screening (urine albumin-to-creatinine ratio)
Cardiovascular risk evaluation
Albuminuria screening is recommended in patients with hypertension, CKD, or diabetes to identify those who may benefit from cardioprotective treatments.
Cardio-kidney-metabolic (CKM) syndrome combines cardiac, renal, and metabolic impairments. Albuminuria, as measured by the urine albumin-to-creatinine ratio, is a biomarker of endothelium-glomerular damage present in CKM syndrome. The gold standard method is quantitative measurement using an immunoenzymatic technique in a laboratory. Albuminuria is continuously associated with cardiovascular risk, even when the increase is modest. The improvement in cardiovascular prognosis achieved with treatments that reduce albuminuria suggests that CKM syndrome is reversible through multiple mechanisms. It is recommended measuring albuminuria in patients with arterial hypertension, chronic kidney disease, or diabetes, and then identifying those who may benefit from cardioprotective treatment.
Building similarity graph...
Analyzing shared references across papers
Loading...
Raphaël Akiba
Gregoire Wuerzner
Didier Locca
Revue Médicale Suisse
University of Lausanne
University Hospital of Lausanne
William Harvey Research Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Akiba et al. (Thu,) reported a other. Measuring albuminuria in patients with hypertension, CKD, or diabetes helps identify those at increased cardiovascular risk who may benefit from cardioprotective treatments.
www.synapsesocial.com/papers/69abc0b85af8044f7a4e95a3 — DOI: https://doi.org/10.53738/revmed.2026.22.952.48360